Chief medical officer Dr Mark Bleakley tells Proactive the company is preparing an application to gain key regulatory approval to begin clinical trials in the US for its psilocybin-assisted psychotherapy development program (Psi-GAD). PsiGAD is a unique and proprietary form of therapy to treat patients with generalised anxiety disorder (GAD). Interim analysis for the Phase 2 Psi-GAD clinical trial in March at Monash University predicted a greater than 85% chance of the trial showing statistically significant benefit for the psilocybin treatment arm versus the placebo arm. Work on the draft IND application comes ahead of final results from the Psi-GAD clinical trial, which are expected in Q4 2023 or Q1 2024.
Plus all the other indications (besides GAD?)
This could be newsworthy!
Maybe worth following up with Joel tonight, Melbourne People.... what are the other indications?
https://youtu.be/tkqAPHEopLM?si=xwQ98svXjuuR5ZAX
GLAH
- Forums
- ASX - By Stock
- IHL
- Ann: Incannex to Prepare IND Application for Psi-GAD
Ann: Incannex to Prepare IND Application for Psi-GAD, page-9
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)